Hydroxyurea to help prevent strokes in sickle cell
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This study looks at whether hydroxyurea (a medicine) can help lower the risk of stroke in children with sickle cell anemia, using screening tests like ultrasound of blood flow. It may help by identifying kids at higher risk and starting treatment if it’s safe for them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your caregiver) can sign the consent form and agree to follow the study plan
- You can come to study visits and stay near the study center for the full study period
- You have a confirmed diagnosis of sickle cell anemia from a blood test (hemoglobin electrophoresis)
- You can take medicine by mouth and follow the hydroxyurea schedule
- You are not sick enough to delay screening—no fever illness, hospital stay, or blood transfusion in the past 2 weeks
- If screening shows risk and hydroxyurea is planned, you must not have reasons it may be unsafe (examples include hydroxyurea allergy, pregnancy/breastfeeding, or prior stroke)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
This study tests how well a higher dose of hydroxyurea works for teenagers with sickle cell anemia living in areas where malaria is common. It looks at safety and how the treatment affects their daily lives.
This trial tests different ways to start hydroxyurea for children with sickle cell anemia. The goal is to find the safest and most effective approach to help manage symptoms and prevent complications.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
This study measures how well blood flows through brain arteries in children with sickle cell disease using a noninvasive ultrasound test. It may help doctors better understand stroke risk and how treatments like hydroxyurea or recent care affect blood flow.
This study looks at whether adjusting the dose of hydroxyurea based on drug levels in the blood works better than the standard approach for treating sickle cell disease in children. It aims to reduce side effects and improve treatment outcomes.
Hear when a new Sickle Cell Anemia in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.